Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMENFD6)

Drug Name
Metelimumab Drug Info
Synonyms CAT-192; SL15A-IgG4; Anti-TGF beta 1 antibodies, Genzyme General/Cambridge Antibody Technologies
Indication
Disease Entry ICD 11 Status REF
Scleroderma 4A42 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMENFD6

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
TGF-beta receptor type I (TGFBR1) TTP4520 TGFR1_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
TGF-beta receptor type I (TGFBR1) DTT TGFBR1 6.123 5.573 5.6 5.399
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Scleroderma
ICD Disease Classification 4A42
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
TGF-beta receptor type I (TGFBR1) DTT TGFBR1 2.62E-01 0.27 1.01
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00043706) Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis. U.S. National Institutes of Health.
2 Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov. 2004 Dec;3(12):1011-22.